About Us
Revolutionizing cervical cancer detection by enabling self-managed and accessible screening that saves lives.
At OncoGenesis, we envision a world where every woman, regardless of geography or circumstance, has access to comprehensive cervical health screening and life-saving early detection of treatable disease. Through our innovative plat form - including the iPap® self-collection device and CerMark® point-of-care diagnostic analysis system - we are breaking down long-standing barriers to screening and healthcare delivery.
By enabling accurate, affordable, and convenient screening, we are not just advancing technology; we are transforming how healthcare reaches women, empowering them to take control of their health, and helping healthcare systems expand access, improve outcomes, and save lives on a global scale.
Our Team
Our Board
Our Advisors
Jovelle Fernandez
MD, PhD, President and CEO
Thomas Umbel – Director
Adam Henry – Director
Adam is a Senior Diagnostics Corporate Development Executive Adam brings over 27 years of
biotechnology industry experience, currently serving as the Head of Strategy, Marketing, and
Business Development at Truvian Health since June 2024 and as a board director for
OncoGenesis since 2022. Prior to Truvian, Adam was Senior Vice President of Corporate
Development at Proof Diagnostics, co leading the effort to successfully sell the company to
Ginkgo Bioworks in August 2023. Adam’s career functional responsibilities have ranged in
scope from corporate strategy, business development (M&A) and marketing, specifically within
the diagnostics arena over the past 15 years, to product development and operations as a
product design engineer earlier in his career at Invitrogen (now part of ThermoFisher Scientific)
and Dura Pharmaceuticals (acquired by Elan Pharmaceuticals). Prior to joining Proof Dx in May
2022, Adam served as Head of Strategy and Business Development at Roche subsidiary
GenMark Dx. Before that, he held senior management roles at Siemens Healthineers, Hologic,
and Gen Probe (acquired by Hologic) in strategy, business development and upstream
marketing. During his tenure, Gen Probe launched several highly innovative products including
the PANTHER® molecular diagnostic system and the APTIMA® HPV screening assay, and the
company’s value doubled, creating nearly $2 billion in value for shareholders, culminating in a
successful sale of the business to Hologic in 2012 for $3.7 billion. In total, Adam has facilitated
nearly $6 billion in molecular diagnostics transactions since 2009. Adam holds an MBA from the
UCLA Anderson School of Management and a BS degree in Mechanical Engineering from the
University of Nevada.
Scott Christensen: Director
Scott brings more than 40 years of medical device and diagnostics industry experience to
OncoGenesis. He has served in various senior management positions within OncoGenesis and
is a member of the Board of Directors. Scott’s in-depth knowledge includes positions at
Johnson & Johnson, 3M Healthcare, and Medtronic. Scott served as CEO of Bentec Medical,
leading to a successful exit to strategic buyers. Scott also served as CEO of start-up Dynatherm
Medical bringing the Company from concept to market to successful acquisition by Care Fusion.
As President of Oridion Medical, he built market presence and revenues, leading to a successful
IPO in Europe. Scott holds a BS in Chemistry from the University of California – Davis and an
MBA from the University of California – Irvine.
